Centella Mauritius Holdings Limited has disclosed a corrected shareholding of 9.90% in Aster DM Quality Care , revising previous reports that cited a 9.7% pledged stake. The disclosure, filed on August 20, 2026, clarifies discrepancies in automated system-driven filings regarding the post-merger equity structure.

The correction arises from the amalgamation of Quality Care India Limited (QCIL) into Aster DM Healthcare Limited. While an earlier disclosure on August 19, 2026, indicated a pledge of 84.4 million shares (9.7%), the updated filing reveals Centella’s total holding is 86,317,533 shares. This represents a significant upward revision in both absolute share count and percentage ownership.

Corrected Shareholding Structure

The new data supersedes the earlier pledge-centric view by detailing the total acquisition mechanics under the Scheme of Amalgamation sanctioned by the NCLT Hyderabad Bench on June 19, 2026. The share exchange ratio was fixed at 977 equity shares of Aster DM Quality Care for every 1,000 shares held in QCIL.

The pre-merger holding of 4,651,992 shares constituted 0.90% of the capital, not the 0.5% previously implied in some contexts relative to the expanded post-merger base. The merger added 81,665,541 shares, bringing the total paid-up equity capital to 871,672,439 shares of ₹10 each.

What the Numbers Show

The discrepancy between the initial 9.7% figure and the corrected 9.90% highlights the complexity of automated disclosures in large corporate actions. The initial report focused on pledged shares (84.4 million), likely reflecting a subset of the total holding or a specific encumbrance tranche. The corrected filing clarifies that Centella’s total voting rights stand at 86.3 million shares. This 0.2 percentage point difference, while seemingly small, represents over 1.8 million additional shares not captured in the initial pledge-focused narrative, underscoring the importance of verifying system-driven disclosures against manual regulatory filings under Regulation 29(1) of the Takeover Code.

Aster DM Quality Care Limited management outlined a strategic roadmap to unlock ₹150–200 crore in annualized synergies, representing a 10–15% uplift in EBITDA, following the July 1, 2026 amalgamation with Quality Care India Limited. During the inaugural earnings conference call on August 5, 2026, Group CEO Varun Khanna emphasized that while the proforma Q1FY27 results reflected strong standalone performance from both entities, true scale-based synergies are yet to be realized. The merged entity reported a 20% year-on-year increase in proforma consolidated revenue to ₹2,597 crore and a 30% surge in Operating EBITDA to ₹576 crore for the quarter ended June 30, 2026.

The Board of Directors approved the unaudited financial results in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by Deloitte Haskins & Sells, the statutory auditors. Management clarified that the standalone net profit was impacted by ₹109.79 crore in exceptional merger-related costs, which are one-time transaction expenses and not indicative of the underlying operating cost base.

Synergy Realization and Operational Leverage

Varun Khanna stated that the previous quarter’s performance was driven by independent efforts of Aster and Quality Care, with no cohesive working between the two platforms. The new “10-point synergy wheel” focuses primarily on indirect cost consumption and procurement leverage. Management expects these synergies to begin materializing in FY27 and annualize in the subsequent financial year. The goal is to reach an EBITDA margin of 24–25% within two to three years post-merger, up from the current proforma margin of 22.2%.

Clinical Expansion and Talent Utilization

The combined platform, comprising 39 hospitals and over 10,800 beds, aims to democratize advanced care by extending super-specialty programs to Tier 2 and Tier 3 cities. Management highlighted significant growth in high-acuity domains: robotic surgeries grew approximately 80%, joint replacements increased by 39%, and transplants rose by 19% year-on-year. A key strategic initiative involves leveraging clinical talent across the network; for instance, Deep Brain Stimulation (DBS) capabilities from Kochi will be extended to other units, and liver transplant teams will serve multiple hospitals to optimize resource utilization.

Regional Performance and Future Pipeline

Kerala emerged as a top performer with 25% revenue growth, driven by volume-led expansion at facilities like Medcity, which crossed ₹100 crore revenue in two months. Karnataka recovered from prior attrition issues, reporting 16% growth after adding 18 doctors in Bengaluru alone. Looking ahead, the company plans to add 4,179 beds over the next three to four years, with 53% of this expansion being brownfield-led. Key upcoming projects include the Trivandrum hospital (targeting H2 FY27), a Hyderabad facility (April 2027), and the Sarjapur project (H2 FY28).

What the Numbers Show

The divergence between the robust proforma EBITDA growth (30%) and revenue growth (20%) underscores the immediate operational efficiency gains even before full merger synergies are realized. The normalization of Aster’s standalone PAT to ₹125 crore, excluding one-time merger costs, reveals a stronger underlying profitability trajectory than the statutory bottom line suggests. Furthermore, the rapid ramp-up of emerging units, such as Kasargod achieving breakeven in nine months, validates the company’s execution capability in greenfield expansions.